^
Association details:
| Biomarker: | ATM mutation |
|---|---|
| Cancer: | Gastrointestinal Cancer |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.
Published date:
01/18/2022
Excerpt:
The study successfully determined the MTD of RUB in combination with nal-IRI and 5FU. Encouraging efficacy was observed in PLA-treated mGI cancers including responses in those harboring ATM and BRCA alterations. The study is proceeding to evaluate the efficacy of the combination in metastatic pancreas cancer pts with and without BRCA1/2 or PALB2 alterations.
Secondary therapy:
5-fluorouracil + irinotecan liposomal
DOI:
10.1200/JCO.2022.40.4_suppl.563
Trial ID:
